• News
  • Cases
  • Downloads
Taplow News
Taplow recently welcomed its new partner firm in Africa and the news has gathered a lot of interest from media outlets worldwide, Hunt Scanlon being the latest outlet to report on the growth of the continent and Taplow.
Read More
Taplow has been listed for the 3rd year in a row in the Hunt Scanlon Global 25 search firm listing.
Read More
Katrin Dambrot, Managing Director at Taplow USA and President of the Financial Women’s Association of New York (FWA) had the privilege of ringing the opening bell at the Toronto Stock Exchange (TSX) on April 26, 2017 as part of the FWA’s International conference to Toronto and Vancouver marking FWA’s recognition of Canada’s 150th Anniversary.
Read More
Page 4 of 7 First 23[4]56 Last

CEO FOR A SPORTS:

Situation: A Finnish, mainly nationally operating sports company needed new CEO as the old one was about to retire. As sports business is one of the competence areas of our Finnish partner, we ended up delivering this search.

Read more …

For further Information please contac Timo Toivanen, Finland

 

 

CEO FOR LOGISTICS:

Situation: One of the largest globally operating Logistics companies was in a need of new CIO for Finland. As Logistics and Value Chain is one of the competence areas of our Finnish partner, we ended up delivering this search.

Read more …

For further Information please contac Timo Toivanen, Finland

White Papers
  • India – The new R&D hub for Automotive

    Taplow India have conducted an in-depth review of the Automotive sector in India, For further information contact Sangeeta Sabharwal, India

    Click Here
  • Maysam Rizvi reviews the Banking Tech Revolution.

    Capital is more expensive, costs are higher and prices have gone down… the technology revolution has become a necessity.

    Click Here
  • EVOLVING BUSINESS UNITS Market Access thus becoming “transversal”

    The pharmaceutical market, in regards to the price component covered by the NHS, has been, until today, characterised by the presence of drugs of high therapeutic value, such as cancer-drugs, rheumatologic drugs, anti-infection drugs and drugs for the treatment of chronic illnesses, the vast majority of which have either seen their patent expire recently or will see it expire in the next two years.

    Click Here
  • BUSINESS CYCLES

    Present Human Capital Opportunities and Challenges:

    Click Here